US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Bicara Therapeutics

23.20

+0.39001.71%

Post-market: 23.540.3400+1.47%17:37 EDT

Volume:426.34K

Turnover:9.92M

Market Cap:1.54B

PE:-7.46

High:23.62

Open:22.88

Low:22.51

Close:22.81

52wk High:30.99

52wk Low:10.30

Shares:66.17M

Float Shares:36.76M

Volume Ratio:0.80

T/O Rate:1.16%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1097

EPS(LYR):-2.5230

ROE:-41.01%

ROA:-26.14%

PB:3.27

PE(LYR):-9.20

Loading ...

Overview Company News Filings

Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of USD 817,447.74 Common Shares

Citizens healthcare analysts hold an analyst/industry conference call

Bicara Therapeutics Grants 191,425 Inducement Stock Options Priced at $28.91 Per Share

Bicara Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Bicara Therapeutics Holds 2026 Annual Stockholder Meeting

Bicara Therapeutics shareholders re-elect Bowden, Ng as Class II directors

Goldman Sachs Keeps Their Hold Rating on Bicara Therapeutics Inc. (BCAX)

Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data

Bicara Therapeutics posts ASCO presentation on ficerafusp alfa plus pembrolizumab in HPV-negative head and neck cancer

Bicara Therapeutics CFO Ivan Hyep disposes of common shares worth $187,883.32

Wedbush Remains a Buy on Bicara Therapeutics Inc. (BCAX)

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)

Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)

Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa

Bicara Therapeutics Inc - Phase 1B Study Shows Deep, Durable Responses and Well-Tolerated Safety Profile

THOMSON REUTERS

Bicara Therapeutics Inc - 1500Mg Ficerafusp Alfa Plus Pembrolizumab Shows 31% 3-Year Overall Survival in 1L R/M Hpv-Negative Hnscc

THOMSON REUTERS

Bicara says ficerafusp alfa plus pembrolizumab shows 31% three-year survival in Phase 1b HNSCC

Bicara Therapeutics management to meet with Cantor

Bicara CEO Claire Mazumdar sells $300,000 common shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/BCAX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BCAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":23.2,"timestamp":1789416000000,"preClose":22.81,"halted":0,"volume":426342,"hourTrading":{"tag":"盘后","latestPrice":23.54,"preClose":23.2,"latestTime":"17:37 EDT","volume":22478,"amount":521491.330806,"timestamp":1789421848874,"change":0.34,"changeRate":0.014655,"amplitude":0.014655},"delay":0,"changeRate":0.017097764138535757,"floatShares":36762300,"shares":66172934,"eps":-3.109661,"marketStatus":"Post-Mkt","change":0.39,"latestTime":"09-14 18:23:08 EDT","open":22.88,"high":23.618,"low":22.51,"amount":9921167.209506,"amplitude":0.048575,"askPrice":23.65,"askSize":84,"bidPrice":22.75,"bidSize":87,"shortable":3,"etf":0,"ttmEps":-3.109661,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789430400000},"marketStatusCode":4,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":22.81,"preHourTrading":{"tag":"盘前","latestPrice":22.9,"preClose":22.81,"latestTime":"09:29 EDT","volume":41,"amount":959.599793,"timestamp":1789392599505,"change":0.09,"changeRate":0.003946,"amplitude":0.039018},"postHourTrading":{"tag":"盘后","latestPrice":23.54,"preClose":23.2,"latestTime":"17:37 EDT","volume":22478,"amount":521491.330806,"timestamp":1789421848874,"change":0.34,"changeRate":0.014655,"amplitude":0.014655},"volumeRatio":0.797412,"impliedVol":0.4776,"impliedVolPercentile":0.6693},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BCAX\",,,,,undefined,":{"symbol":"BCAX","floatShares":36762300,"roa":"-26.14%","roe":"-41.01%","lyrEps":-2.523003,"volumeRatio":0.797412,"shares":66172934,"dividePrice":0,"high":23.618,"amplitude":0.048575,"preClose":22.81,"low":22.51,"week52Low":10.295,"pbRate":"3.27","week52High":30.99,"institutionHeld":0,"latestPrice":23.2,"committee":0.017544,"eps":-3.109661,"divideRate":0,"volume":426342,"delay":0,"ttmEps":-3.109661,"open":22.88,"prevYearClose":16.83,"prevWeekClose":22.81,"prevMonthClose":23.12,"prevQuarterClose":29.69,"fiveDayClose":23.17,"twentyDayClose":24.28,"sixtyDayClose":22.92},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BCAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"BCAX","fiscalQuarterEnding":"2026/06","expectedEps":-0.77,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.82},{"market":"US","date":"2026-05-11","symbol":"BCAX","fiscalQuarterEnding":"2026/03","expectedEps":-0.64,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"pre","actualEps":-0.93},{"market":"US","date":"2026-03-30","symbol":"BCAX","fiscalQuarterEnding":"2025/12","expectedEps":-0.72,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774843200000,"reportTimeType":"pre","actualEps":-0.68},{"market":"US","date":"2025-11-10","symbol":"BCAX","fiscalQuarterEnding":"2025/09","expectedEps":-0.55,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762750800000,"reportTimeType":"pre","actualEps":-0.67},{"market":"US","date":"2025-08-12","symbol":"BCAX","fiscalQuarterEnding":"2025/06","expectedEps":-0.54,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-0.5}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BCAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BCAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.5333,"hold":0.1333,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5333,"analysts":15,"updateTime":1787284800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/BCAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"BCAX","date":"2026-09-11","current":-7.46062,"percent":0.680723,"low":-22.704836,"twenty":-12.207874,"median":-9.430022,"eighty":-6.958786,"high":-5.144536,"avg":-10.45355,"sd":4.085542,"marketCap":1528594775},"quantilePoints":[{"date":"2024-09-13","current":-12.837909,"twenty":-12.837909,"median":-12.837909,"eighty":-12.837909,"marketCap":832435719},{"date":"2024-09-20","current":-20.633135,"twenty":-21.391361,"median":-20.283845,"eighty":-14.007791,"marketCap":1337893755},{"date":"2024-09-27","current":-21.555755,"twenty":-21.594337,"median":-21.446718,"eighty":-19.006626,"marketCap":1397718272},{"date":"2024-10-04","current":-19.962139,"twenty":-21.575885,"median":-21.337681,"eighty":-19.559541,"marketCap":1294385015},{"date":"2024-10-11","current":-15.936161,"twenty":-21.540658,"median":-20.570229,"eighty":-18.732598,"marketCap":1033332575},{"date":"2024-10-18","current":-17.143955,"twenty":-21.466848,"median":-20.283845,"eighty":-16.808457,"marketCap":1111648307},{"date":"2024-10-25","current":-18.964032,"twenty":-21.403103,"median":-19.23243,"eighty":-16.959431,"marketCap":1229665764},{"date":"2024-10-31","current":-19.878264,"twenty":-21.362844,"median":-19.23243,"eighty":-17.02653,"marketCap":1288946422},{"date":"2024-11-08","current":-19.79439,"twenty":-21.337681,"median":-19.82794,"eighty":-17.143955,"marketCap":1283507830},{"date":"2024-11-15","current":-20.345116,"twenty":-21.127995,"median":-19.949558,"eighty":-18.418848,"marketCap":1210086831},{"date":"2024-11-22","current":-16.257533,"twenty":-21.102833,"median":-19.82794,"eighty":-17.143955,"marketCap":966965549},{"date":"2024-11-29","current":-19.02049,"twenty":-20.975343,"median":-19.458892,"eighty":-17.009755,"marketCap":1131300719},{"date":"2024-12-06","current":-17.876882,"twenty":-20.695202,"median":-19.01323,"eighty":-17.12047,"marketCap":1063281195},{"date":"2024-12-13","current":-16.509127,"twenty":-20.532485,"median":-19.005969,"eighty":-17.12047,"marketCap":981929844},{"date":"2024-12-20","current":-15.187116,"twenty":-20.493904,"median":-18.892739,"eighty":-16.769874,"marketCap":903299275},{"date":"2024-12-27","current":-17.49263,"twenty":-20.458153,"median":-18.854995,"eighty":-16.764842,"marketCap":1040426635},{"date":"2025-01-03","current":-15.484454,"twenty":-20.399979,"median":-18.727694,"eighty":-16.641786,"marketCap":920984351},{"date":"2025-01-10","current":-13.952019,"twenty":-20.332862,"median":-18.565256,"eighty":-16.325863,"marketCap":829838189},{"date":"2025-01-17","current":-10.868852,"twenty":-20.271506,"median":-18.306879,"eighty":-15.951961,"marketCap":646457553},{"date":"2025-01-24","current":-10.951191,"twenty":-20.22215,"median":-18.224539,"eighty":-15.55307,"marketCap":651354959},{"date":"2025-01-31","current":-11.811185,"twenty":-20.138275,"median":-17.666458,"eighty":-14.949245,"marketCap":702505641},{"date":"2025-02-07","current":-11.52757,"twenty":-20.11652,"median":-17.561246,"eighty":-13.156068,"marketCap":685636799},{"date":"2025-02-14","current":-12.003311,"twenty":-19.978914,"median":-17.49263,"eighty":-12.003311,"marketCap":713932921},{"date":"2025-02-21","current":-12.643731,"twenty":-19.965494,"median":-17.085242,"eighty":-11.997822,"marketCap":752023854},{"date":"2025-02-28","current":-11.307997,"twenty":-19.942009,"median":-16.815614,"eighty":-11.891694,"marketCap":672577050},{"date":"2025-03-07","current":-14.409462,"twenty":-19.890007,"median":-16.73236,"eighty":-11.891694,"marketCap":857045999},{"date":"2025-03-14","current":-12.213735,"twenty":-19.838005,"median":-16.60519,"eighty":-11.893524,"marketCap":726448513},{"date":"2025-03-21","current":-11.975864,"twenty":-19.8011,"median":-16.394587,"eighty":-11.882546,"marketCap":712300452},{"date":"2025-03-28","current":-10.745093,"twenty":-19.525992,"median":-16.092853,"eighty":-11.882546,"marketCap":730612568},{"date":"2025-04-04","current":-9.486153,"twenty":-19.364339,"median":-15.936742,"eighty":-11.721526,"marketCap":645010946},{"date":"2025-04-11","current":-8.139007,"twenty":-19.311424,"median":-15.55307,"eighty":-11.500123,"marketCap":553411758},{"date":"2025-04-17","current":-9.430022,"twenty":-19.133936,"median":-15.269456,"eighty":-11.355571,"marketCap":641194313},{"date":"2025-04-25","current":-12.533268,"twenty":-19.02049,"median":-15.045308,"eighty":-11.297018,"marketCap":852199585},{"date":"2025-05-02","current":-11.795546,"twenty":-19.011777,"median":-14.409462,"eighty":-11.329955,"marketCap":802038125},{"date":"2025-05-09","current":-10.531076,"twenty":-18.980807,"median":-14.002338,"eighty":-11.242349,"marketCap":716060542},{"date":"2025-05-16","current":-8.546663,"twenty":-18.933837,"median":-13.265854,"eighty":-11.091295,"marketCap":789139074},{"date":"2025-05-23","current":-9.249533,"twenty":-18.888545,"median":-12.837909,"eighty":-10.95668,"marketCap":854037173},{"date":"2025-05-30","current":-5.575709,"twenty":-18.86506,"median":-12.634583,"eighty":-10.80298,"marketCap":514821897},{"date":"2025-06-06","current":-6.514837,"twenty":-18.854995,"median":-12.506498,"eighty":-10.643069,"marketCap":601534484},{"date":"2025-06-13","current":-6.833787,"twenty":-18.81138,"median":-12.341819,"eighty":-10.421008,"marketCap":630984042},{"date":"2025-06-20","current":-5.569802,"twenty":-18.738652,"median":-12.190862,"eighty":-10.145292,"marketCap":514276535},{"date":"2025-06-27","current":-5.203601,"twenty":-18.705007,"median":-12.094799,"eighty":-9.441248,"marketCap":480464080},{"date":"2025-07-03","current":-5.333543,"twenty":-18.687321,"median":-12.003311,"eighty":-9.12531,"marketCap":492462048},{"date":"2025-07-11","current":-5.859219,"twenty":-18.443191,"median":-11.975864,"eighty":-8.617541,"marketCap":540999282},{"date":"2025-07-18","current":-6.881039,"twenty":-18.418848,"median":-11.920971,"eighty":-8.339475,"marketCap":635346939},{"date":"2025-07-25","current":-7.04642,"twenty":-18.306879,"median":-11.898098,"eighty":-7.625808,"marketCap":650617080},{"date":"2025-08-01","current":-6.562089,"twenty":-18.251986,"median":-11.884376,"eighty":-7.016887,"marketCap":605897381},{"date":"2025-08-08","current":-6.0246,"twenty":-18.224539,"median":-11.847781,"eighty":-6.881039,"marketCap":556269423},{"date":"2025-08-15","current":-6.063601,"twenty":-17.876882,"median":-11.795546,"eighty":-6.786535,"marketCap":622562015},{"date":"2025-08-22","current":-6.180515,"twenty":-17.675607,"median":-11.648291,"eighty":-6.638873,"marketCap":634565840},{"date":"2025-08-29","current":-6.329315,"twenty":-17.657309,"median":-11.619058,"eighty":-6.514837,"marketCap":649843436},{"date":"2025-09-05","current":-6.409029,"twenty":-17.584119,"median":-11.52757,"eighty":-6.407746,"marketCap":658027862},{"date":"2025-09-12","current":-6.366515,"twenty":-17.562161,"median":-11.3858,"eighty":-6.401771,"marketCap":653662835},{"date":"2025-09-19","current":-5.877601,"twenty":-17.506353,"median":-11.36289,"eighty":-6.371769,"marketCap":603465021},{"date":"2025-09-26","current":-5.686286,"twenty":-17.49263,"median":-11.294273,"eighty":-6.328252,"marketCap":583822398},{"date":"2025-10-03","current":-8.880173,"twenty":-17.49263,"median":-11.226216,"eighty":-6.328252,"marketCap":911745073},{"date":"2025-10-10","current":-9.712715,"twenty":-17.21369,"median":-11.089726,"eighty":-6.337818,"marketCap":997223830},{"date":"2025-10-17","current":-9.936118,"twenty":-17.050015,"median":-11.051829,"eighty":-6.344195,"marketCap":1020161070},{"date":"2025-10-24","current":-8.999952,"twenty":-16.959431,"median":-10.928319,"eighty":-6.362264,"marketCap":924043110},{"date":"2025-10-31","current":-8.755273,"twenty":-16.841022,"median":-10.759065,"eighty":-6.371769,"marketCap":898921371},{"date":"2025-11-07","current":-7.749959,"twenty":-16.783048,"median":-10.701761,"eighty":-6.376332,"marketCap":795703789},{"date":"2025-11-14","current":-6.428441,"twenty":-16.754777,"median":-10.617258,"eighty":-6.376332,"marketCap":781190607},{"date":"2025-11-21","current":-7.293982,"twenty":-16.72193,"median":-10.425573,"eighty":-6.385646,"marketCap":886371951},{"date":"2025-11-28","current":-8.366891,"twenty":-16.703998,"median":-10.156917,"eighty":-6.394149,"marketCap":1016752992},{"date":"2025-12-05","current":-8.457052,"twenty":-16.641786,"median":-10.005266,"eighty":-6.400929,"marketCap":1027709382},{"date":"2025-12-12","current":-8.497624,"twenty":-16.572254,"median":-9.798232,"eighty":-6.406463,"marketCap":1032639757},{"date":"2025-12-19","current":-7.952153,"twenty":-16.525595,"median":-9.707395,"eighty":-6.409029,"marketCap":966353598},{"date":"2025-12-26","current":-7.785356,"twenty":-16.417495,"median":-9.581658,"eighty":-6.416794,"marketCap":946084276},{"date":"2026-01-02","current":-7.587003,"twenty":-16.275544,"median":-9.536519,"eighty":-6.433907,"marketCap":921980218},{"date":"2026-01-09","current":-7.465287,"twenty":-16.224597,"median":-9.44371,"eighty":-6.465223,"marketCap":907189092},{"date":"2026-01-16","current":-7.523891,"twenty":-16.076385,"median":-9.207398,"eighty":-6.505387,"marketCap":914310745},{"date":"2026-01-23","current":-7.929613,"twenty":-16.010514,"median":-9.12531,"eighty":-6.514837,"marketCap":963614500},{"date":"2026-01-30","current":-7.623067,"twenty":-15.937323,"median":-9.082399,"eighty":-6.531258,"marketCap":926362774},{"date":"2026-02-06","current":-6.807115,"twenty":-15.936161,"median":-9.042505,"eighty":-6.562089,"marketCap":827207445},{"date":"2026-02-13","current":-6.338281,"twenty":-15.928174,"median":-8.933537,"eighty":-6.562089,"marketCap":770234217},{"date":"2026-02-20","current":-6.951372,"twenty":-15.628091,"median":-8.853601,"eighty":-6.527974,"marketCap":844737669},{"date":"2026-02-27","current":-8.759817,"twenty":-15.498177,"median":-8.759817,"eighty":-6.531952,"marketCap":1064501760},{"date":"2026-03-06","current":-9.890416,"twenty":-15.312456,"median":-8.853601,"eighty":-6.556096,"marketCap":1201893200},{"date":"2026-03-13","current":-10.269994,"twenty":-15.203584,"median":-8.927397,"eighty":-6.566815,"marketCap":1248019912},{"date":"2026-03-20","current":-10.045455,"twenty":-15.15052,"median":-9.021228,"eighty":-6.577062,"marketCap":1220733688},{"date":"2026-03-27","current":-10.114955,"twenty":-14.98767,"median":-9.07442,"eighty":-6.589163,"marketCap":1229179424},{"date":"2026-04-02","current":-9.728723,"twenty":-14.625375,"median":-9.090377,"eighty":-6.609609,"marketCap":1342077333},{"date":"2026-04-10","current":-10.431089,"twenty":-14.409462,"median":-9.148523,"eighty":-6.631964,"marketCap":1438968770},{"date":"2026-04-17","current":-11.356504,"twenty":-14.321633,"median":-9.207398,"eighty":-6.63974,"marketCap":1566629784},{"date":"2026-04-24","current":-10.839221,"twenty":-14.136826,"median":-9.386913,"eighty":-6.653842,"marketCap":1495270551},{"date":"2026-05-01","current":-10.241261,"twenty":-13.992274,"median":-9.457397,"eighty":-6.668268,"marketCap":1412781895},{"date":"2026-05-08","current":-10.980156,"twenty":-13.748914,"median":-9.551117,"eighty":-6.6946,"marketCap":1514712543},{"date":"2026-05-15","current":-8.624637,"twenty":-13.404917,"median":-9.536519,"eighty":-6.716778,"marketCap":1356784832},{"date":"2026-05-22","current":-8.703992,"twenty":-13.199982,"median":-9.448315,"eighty":-6.737692,"marketCap":1369268567},{"date":"2026-05-29","current":-9.084061,"twenty":-13.028804,"median":-9.388604,"eighty":-6.752117,"marketCap":1429059085},{"date":"2026-06-05","current":-8.524399,"twenty":-12.837909,"median":-9.249533,"eighty":-6.75968,"marketCap":1341015905},{"date":"2026-06-12","current":-8.887762,"twenty":-12.760238,"median":-9.180782,"eighty":-6.769997,"marketCap":1398178268},{"date":"2026-06-18","current":-9.572721,"twenty":-12.640072,"median":-9.17593,"eighty":-6.781418,"marketCap":1505932608},{"date":"2026-06-26","current":-11.001111,"twenty":-12.607001,"median":-9.207398,"eighty":-6.784967,"marketCap":1730639830},{"date":"2026-07-02","current":-12.074492,"twenty":-12.533268,"median":-9.343805,"eighty":-6.786535,"marketCap":1899498766},{"date":"2026-07-10","current":-12.396089,"twenty":-12.533268,"median":-9.434628,"eighty":-6.792442,"marketCap":1950090742},{"date":"2026-07-17","current":-11.52736,"twenty":-12.506498,"median":-9.486153,"eighty":-6.807115,"marketCap":1813426701},{"date":"2026-07-24","current":-11.581656,"twenty":-12.437044,"median":-9.561678,"eighty":-6.833787,"marketCap":1821968204},{"date":"2026-07-31","current":-10.971875,"twenty":-12.407622,"median":-9.577189,"eighty":-6.841301,"marketCap":1726040559},{"date":"2026-08-07","current":-11.489771,"twenty":-12.396924,"median":-9.702195,"eighty":-6.849841,"marketCap":1807513353},{"date":"2026-08-14","current":-8.435699,"twenty":-12.359992,"median":-9.679126,"eighty":-6.875132,"marketCap":1563666430},{"date":"2026-08-21","current":-8.707012,"twenty":-12.33633,"median":-9.572721,"eighty":-6.915667,"marketCap":1613957860},{"date":"2026-08-28","current":-8.864088,"twenty":-12.269802,"median":-9.54708,"eighty":-6.936947,"marketCap":1643073951},{"date":"2026-09-04","current":-8.332171,"twenty":-12.221805,"median":-9.457397,"eighty":-6.949118,"marketCap":1544476279},{"date":"2026-09-11","current":-8.246494,"twenty":-12.207874,"median":-9.430022,"eighty":-6.958786,"marketCap":1528594775}],"updateTime":1789424587474},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BCAX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2650137885","title":"Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of USD 817,447.74 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2650137885","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650137885?lang=en_us&edition=fundamental","pubTime":"2026-07-11 04:12","pubTimestamp":1783714327,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics President and COO Ryan Cohlhepp reports disposal of USD 817,447.74 common sharesBicara Therapeutics President, COO, director Ryan Cohlhepp cut his direct common-stock stake to 181,641 shares.Sold 28,750 shares on July 8-9 at prices around USD 28.76 to USD 30.35.Exercised options for 18,750 shares at USD 3.79 on July 8.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260710:nNDL8XkqsY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics President and COO Ryan Cohlhepp Reports Disposal of USD 817,447.74 Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649937242","title":"Citizens healthcare analysts hold an analyst/industry conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2649937242","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649937242?lang=en_us&edition=fundamental","pubTime":"2026-07-08 03:55","pubTimestamp":1783454121,"startTime":"0","endTime":"0","summary":"Healthcare Analysts discuss understanding the developing landscape in Colorectal Cancer (CRC) (relevant companies BCAX, CTMX, EXEL, INBX, INCY, LYE...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citizens-healthcare-analysts-hold-an-analyst-industry-conference-call-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citizens-healthcare-analysts-hold-an-analyst-industry-conference-call-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IXJ","LU0456854461.SGD","VHT","XLV","TCAF","BCAX","XBI","LABU","NOBL","CRC","BK4588","INBX","BK4139","BK4550","CGCV","BK4213","LU0266512127.USD","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648507746","title":"Bicara Therapeutics Grants 191,425 Inducement Stock Options Priced at $28.91 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2648507746","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648507746?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:30","pubTimestamp":1782995425,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics grants 191,425 inducement stock options priced at $28.91 per shareBicara Therapeutics granted inducement stock options on July 1, 2026 to four new employees covering 191,425 shares","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL28glZR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","SG9999014013.SGD","SG9999014039.USD","IE00BN0W2T93.GBP","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","BK4139","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4112","IE00BN0W2W23.USD","LU0314104364.USD","IE00BKPKM429.USD","BK4585","LU2095319765.USD","IE00BGHQF748.EUR","NDAQ","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648421507","title":"Bicara Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648421507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648421507?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:30","pubTimestamp":1782995400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nTUA3YWGF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648004725","title":"Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648004725","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648004725?lang=en_us&edition=fundamental","pubTime":"2026-07-02 20:30","pubTimestamp":1782995400,"startTime":"0","endTime":"0","summary":"BOSTON, July  02, 2026  (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/02/3321313/0/en/Bicara-Therapeutics-Announces-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYTNYN87.SGD","BK4108","LU1023057109.AUD","01698","LU0359202008.SGD","LU2039709279.SGD","BK4535","LU0359201612.USD","BK4571","LU0828238088.HKD","BK4526","BK4548","BK4552","BK4565","IE00B12V2V27.USD","SG9999011746.SGD","BK4139","BK4509","BK4531","BCAX","IE00BYQNZ168.SGD","LU0269904917.USD","LU0509642566.USD","BK4563","LU0456842615.SGD","TME"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642479381","title":"Bicara Therapeutics Holds 2026 Annual Stockholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642479381","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642479381?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:59","pubTimestamp":1781125151,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. ( ($BCAX) ) has issued an update. On June 9, 2026, Bicara Therapeutics Inc. held its 2026 annual meeting of stockholders, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-holds-2026-annual-stockholder-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-therapeutics-holds-2026-annual-stockholder-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642111475","title":"Bicara Therapeutics shareholders re-elect Bowden, Ng as Class II directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2642111475","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642111475?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:06","pubTimestamp":1781121985,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics held its annual shareholder meeting on June 9, 2026.Shareholders backed the selection of Christopher Bowden, M.D. and Carolyn Ng, Ph.D. to serve as directors.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDLchfRx7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640910709","title":"Goldman Sachs Keeps Their Hold Rating on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2640910709","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640910709?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:57","pubTimestamp":1780401472,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Hold rating on Bicara Therapeutics Inc., with a price target of $18.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-keeps-their-hold-rating-on-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-keeps-their-hold-rating-on-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640495548","title":"Analyst Reiterates Buy on Bicara, Keeps 12-Month Price Target Unchanged at $42 on Encouraging Ficerafusp Alfa Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2640495548","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640495548?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:55","pubTimestamp":1780311337,"startTime":"0","endTime":"0","summary":"In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Bicara Therapeutics Inc., with a price target of $42.00. R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-bicara-keeps-12-month-price-target-unchanged-at-42-on-encouraging-ficerafusp-alfa-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-bicara-keeps-12-month-price-target-unchanged-at-42-on-encouraging-ficerafusp-alfa-data-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639551609","title":"Bicara Therapeutics posts ASCO presentation on ficerafusp alfa plus pembrolizumab in HPV-negative head and neck cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2639551609","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639551609?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:03","pubTimestamp":1780142593,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics published an ASCO poster on ficerafusp alfa with pembrolizumab in first-line R/M HPV-negative HNSCC with PD-L1 CPS ≥1.Pooled analysis linked deep response  to longer DOR, PFS, OS versus PR <80%.Median DOR 31.6 months for deep response versus 8.2 months for PR <80%; hazard ratio 0.31 .Median PFS 36.9 months versus 10.9 months; hazard ratio 0.35 .Median OS not reached versus 33.6 months; hazard ratio 0.37 .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief on May 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260530:nNDL3tyXRr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638230985","title":"Bicara Therapeutics CFO Ivan Hyep disposes of common shares worth $187,883.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2638230985","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638230985?lang=en_us&edition=fundamental","pubTime":"2026-05-27 05:48","pubTimestamp":1779832126,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics CFO Ivan Hyep sold 9,200 common shares on May 21 at a weighted average USD 20.42.He also exercised stock options for 9,200 shares at USD 3.79 on the same day.Hyep held 145,355 common shares following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 26, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nNDL1kS7mH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara Therapeutics CFO Ivan Hyep disposes of common shares worth $187,883.32","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638054970","title":"Wedbush Remains a Buy on Bicara Therapeutics Inc. (BCAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638054970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638054970?lang=en_us&edition=fundamental","pubTime":"2026-05-27 00:55","pubTimestamp":1779814516,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on Bicara Therapeutics Inc. today and set a price target of $30.00. In addition to Wedbush, Bicara Therapeu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-bicara-therapeutics-inc-bcax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638301545","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsored ADR (ABVX) and Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2638301545","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638301545?lang=en_us&edition=fundamental","pubTime":"2026-05-26 22:50","pubTimestamp":1779807036,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bicara Therapeutics Inc. (BCAX), Abivax SA Sponsor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bicara-therapeutics-inc-bcax-abivax-sa-sponsored-adr-abvx-and-arcutis-biotherapeutics-arqt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bicara-therapeutics-inc-bcax-abivax-sa-sponsored-adr-abvx-and-arcutis-biotherapeutics-arqt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARQT","XBI","BK4588","BCAX","LABU","LU0128526141.USD","HCSG","BK4139","LU0029874061.USD","BK4581","XLV","AAVXF","BK4585","BK4137","ABVX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637345356","title":"Analysts Are Bullish on These Healthcare Stocks: Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637345356","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637345356?lang=en_us&edition=fundamental","pubTime":"2026-05-23 00:01","pubTimestamp":1779465665,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bicara Therapeutics Inc. (BCAX), Agios Pharma (AGIO)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-bicara-therapeutics-inc-bcax-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-bicara-therapeutics-inc-bcax-agios-pharma-agio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGIO","BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637639323","title":"Bicara Highlights Durable Three-Year Data for Ficerafusp Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2637639323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637639323?lang=en_us&edition=fundamental","pubTime":"2026-05-22 07:47","pubTimestamp":1779407257,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Bicara Therapeutics Inc. ( ($BCAX) ). On May 21, 2026, Bicara Therapeutics reported three-year follow-up data f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bicara-highlights-durable-three-year-data-for-ficerafusp-alfa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bicara-highlights-durable-three-year-data-for-ficerafusp-alfa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637317357","title":"Bicara Therapeutics Inc - Phase 1B Study Shows Deep, Durable Responses and Well-Tolerated Safety Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2637317357","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637317357?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:08","pubTimestamp":1779397696,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0WM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637035731","title":"Bicara Therapeutics Inc - 1500Mg Ficerafusp Alfa Plus Pembrolizumab Shows 31% 3-Year Overall Survival in 1L R/M Hpv-Negative Hnscc","url":"https://stock-news.laohu8.com/highlight/detail?id=2637035731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637035731?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:08","pubTimestamp":1779397696,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0WM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637352703","title":"Bicara says ficerafusp alfa plus pembrolizumab shows 31% three-year survival in Phase 1b HNSCC","url":"https://stock-news.laohu8.com/highlight/detail?id=2637352703","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637352703?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:01","pubTimestamp":1779397317,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics reported three-year follow-up results from its Phase 1/1b study of ficerafusp alfa with pembrolizumab in first-line recurrent or metastatic HPV-negative head and neck cancer.The results were slated for presentation at the 2026 ASCO Annual Meeting, with the updated dataset pointing to durable responses and longer-term survival that the company attributed to TGF-β inhibition.The readout underpins the company’s ongoing FORTIFI-HN01 pivotal program using the selected weekly dose regimen in combination with pembrolizumab.Bicara also plans to start a separate study in the third quarter of 2026 to test a loading-dose regimen followed by less frequent maintenance dosing to support longer-term treatment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL49cbby:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637352019","title":"Bicara Therapeutics management to meet with Cantor","url":"https://stock-news.laohu8.com/highlight/detail?id=2637352019","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637352019?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:00","pubTimestamp":1779397225,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on May 26 hosted by Cantor. Published first on TheFly – the ultimate source for real-time, market-moving breaking fi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-management-to-meet-with-cantor-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bicara-therapeutics-management-to-meet-with-cantor-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637878696","title":"Bicara CEO Claire Mazumdar sells $300,000 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2637878696","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637878696?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:08","pubTimestamp":1779307736,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics CEO and director Claire Mazumdar cut her stake to 362,152 shares on May 18.The filing shows sales of 15,000 shares at weighted average prices of USD 19.96 and USD 20.35.She also acquired 15,000 shares at USD 3.79 through an option exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bicara Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDL3wS0Wb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Bicara CEO Claire Mazumdar sells $300,000 common shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":3,"totalSize":130,"code":"91000000","status":"200"}]}}